Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

51.4%

36 terminated/withdrawn out of 70 trials

Success Rate

41.9%

-44.6% vs industry average

Late-Stage Pipeline

3%

2 trials in Phase 3/4

Results Transparency

162%

42 of 26 completed trials have results

Key Signals

4 recruiting42 with results31 terminated5 withdrawn

Enrollment Performance

Analytics

Phase 2
48(72.7%)
Phase 1
13(19.7%)
N/A
2(3.0%)
Phase 3
2(3.0%)
Early Phase 1
1(1.5%)
66Total
Phase 2(48)
Phase 1(13)
N/A(2)
Phase 3(2)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (70)

Showing 20 of 70 trials
NCT05956041Phase 2Recruiting

Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas

Role: collaborator

NCT05583708Phase 2Recruiting

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

Role: collaborator

NCT03971409Phase 2Active Not Recruiting

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer

Role: collaborator

NCT03317158Phase 1Recruiting

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Role: collaborator

NCT04848337Phase 2Active Not Recruiting

Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Role: collaborator

NCT04858256Phase 2Recruiting

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Role: collaborator

NCT03547999Phase 2Terminated

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Role: collaborator

NCT03117309Phase 2Completed

Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma

Role: collaborator

NCT02365766Phase 1Completed

Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects

Role: collaborator

NCT03272217Phase 2Terminated

Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer

Role: collaborator

NCT02581215Phase 2Completed

Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer

Role: collaborator

NCT01074970Phase 2Completed

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Role: lead

NCT02581059Phase 2Terminated

Efficacy of Ginseng for Patients on Regorafenib

Role: collaborator

NCT03451331Phase 2Completed

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Role: collaborator

NCT03396471Phase 2Terminated

Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

Role: lead

NCT01215136Phase 2Terminated

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Role: collaborator

NCT01177683Phase 1Terminated

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Role: collaborator

NCT02643043Not ApplicableCompleted

UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch

Role: collaborator

NCT02101385Phase 2Completed

Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer

Role: collaborator

NCT02343952Phase 2Completed

Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

Role: collaborator